Titan BiotechBOM:524717 +0.16%51 Interest Coverage is 35.47 as of Mar. 2026, which is 26% above its 10-year median of 28.25. GuruFocus rates BOM:524717 with a GF Score™ of 51/100 and a GF Value™ of ₹144.55 (Significantly Overvalued). The stock has 2 warning signs investors should review. Among 376 Biotechnology companies, Titan Biotech ranks worse than 60.64% on this metric.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's
Operating Income
by its Interest Expense. Titan Biotech's
Operating Income
for the
three
months ended in Mar. 2026 was ₹84 Mil. Titan Biotech's Interest Expense for the
three
months ended in Mar. 2026 was ₹-2 Mil.
Titan Biotech's interest coverage for the quarter that ended in Mar. 2026 was 35.47.
The higher the ratio, the stronger the company's financial strength is.
The historical rank and industry rank for Titan Biotech's Interest Coverage or its related term are showing as below:
BOM:524717'
s Interest Coverage Range Over the Past 10 Years
Min: 2.71 Med: 28.25 Max: 47.88
Current: 36.85
BOM:524717's Interest Coverage is ranked worse than 60.64% of 376
companies
in the Biotechnology industry
Industry Median: 110.86
vs BOM:524717: 36.85
Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.
Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .
Titan Biotech Interest Coverage Related Terms
Titan Biotech Interest Coverage Historical Data
* Premium members only.
The historical data trend for Titan Biotech's Interest Coverage can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
BOM:524717 vs VRTX, REGN, ALNY: Interest Coverage Comparison
For the Biotechnology subindustry, Titan Biotech's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Titan Biotech Interest Coverage vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Titan Biotech's Interest Coverage distribution charts can be found below:
* The bar in red indicates where Titan Biotech's Interest Coverage falls into.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Titan Biotech (BOM:524717) has a Interest Coverage of 35.47 as of Mar. 2026. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Titan Biotech and its competitors. This is 26% above median its historical median of 28.25. Over the past decade, Titan Biotech's Interest Coverage has ranged from 2.71 to 47.88. According to the industry distribution chart, Titan Biotech ranks #228 out of 376 companies in the Biotechnology industry, placing it in the top 60.6%.
Is Titan Biotech's Interest Coverage too high?
Titan Biotech's current Interest Coverage of 35.47 is 26% above median its 10-year median of 28.25. Over the past 10 years, this metric has ranged from a low of 2.71 to a high of 47.88. The Biotechnology industry median Interest Coverage is 110.86. Titan Biotech's value of 35.47 is 68% below this industry median. Based on the distribution chart, Titan Biotech ranks #228 out of 376 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Titan Biotech has a GF Score™ of 51/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Titan Biotech's Interest Coverage compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Titan Biotech ranks #228 out of 376 companies for Interest Coverage. This places Titan Biotech in the lower half of its industry. The industry median Interest Coverage is 110.86. Titan Biotech's value of 35.47 is 68% below this benchmark. Historically, Titan Biotech's own Interest Coverage has ranged from 2.71 to 47.88 over the past decade. While the company's 10-year median is 28.25 vs. the industry median of 110.86, Titan Biotech has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Coverage for a Biotechnology company?
The median Interest Coverage among Biotechnology companies is 110.86, based on 376 companies in the industry. Companies in the top quartile (top 25%) have a Interest Coverage significantly above this median, while those in the bottom quartile fall well below. However, Interest Coverage should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Titan Biotech's current Interest Coverage of 35.47 is 68% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Coverage mean?
A high Interest Coverage can signal that a stock is expensive relative to its fundamentals. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Titan Biotech and its competitors. For the Biotechnology industry, the median Interest Coverage is 110.86 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Titan Biotech's current Interest Coverage is 35.47, which is 26% above median its own 10-year median of 28.25. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Titan Biotech stock overvalued right now?
Based on GuruFocus' analysis, Titan Biotech (BOM:524717) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹144.55, compared to a current price of ₹397.40 — trading 174.9% above its estimated fair value. The current Interest Coverage is 35.47, which is 26% above median its 10-year median of 28.25 and 68% below the Biotechnology industry median of 110.86. Titan Biotech's overall GF Score™ is 51/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Coverage calculated?
Interest Coverage is calculated from a company's financial statements. For Titan Biotech (BOM:524717), the current Interest Coverage is 35.47 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Titan Biotech (BOM:524717) Overvalued in 2026?
Based on GuruFocus' analysis, Titan Biotech stock appears to be overvalued.
The current stock price of ₹397.40 is trading 174.9% above its estimated GF Value™ of ₹144.55.
GuruFocus considers Titan Biotech to be Significantly Overvalued.
Key valuation signals for BOM:524717:
Interest Coverage: 35.47 (26% above median its 10-year median of 28.25)
GF Value™: ₹144.55 vs. price of ₹397.40 (174.9% above fair value)
Industry Position: 68% below the Biotechnology median (#228 of 376)
No single metric tells the full story. See the BOM:524717 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Titan Biotech Ltd is a manufacturer and exporter of biological products. It manufactures biological products such as peptone, malt extract, yeast extract, liver extract, bile extract, culture media, laboratory chemicals, plant growth promoters, and others. The biological products have applications in the field of pharmaceutical, nutraceutical, food and beverages, biotechnology and fermentation, cosmetic, veterinary and animal feed, agriculture industries, and others. The company's business activity falls within a single primary business segment, which is the business of Biological Products. The firm sells its products in India and also exports internationally, of which the majority of the revenue is derived from the sales made in India.
51GF Score
Get the complete analysis for BOM:524717
Interest Coverage is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:524717 has been successfully added to your 
